



U.S. UTILITY PATENT APPLICATION

Title INACTIVE VARIANTS OF THE
HUMAN TELOMERASE CATALYTIC SUBUNIT

Inventor Gregg B. Morin
Oakville, Ontario, Canada

**Filing
Information** Date: November 21, 2001
Express Mail No. EF 279208481 US
Docket: 018/258c

Correspondence J. Michael Schiff
Registration No. 40,253

Geron Corporation
230 Constitution Drive
Menlo Park, CA 94025
Phone: (650) 473-7715
Fax: (650) 473-8654

USPTO Customer No. 022869

Priority

This application is a continuation of U.S. Patent Application 09/128,354, filed August 3, 1998, pending; which is a continuation-in-part of U.S. Patent Application 09/052,864, filed March 31, 1998, now abandoned.

09990080 "112101
TOTAL 09990080

INACTIVE VARIANTS OF THE HUMAN TELOMERASE CATALYTIC SUBUNIT

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Patent Application 09/128,354, filed August 3, 1998, pending; which is a continuation-in-part of U.S. Patent Application 09/052,864, filed March 31, 1998, now abandoned.

The aforelisted priority applications are hereby incorporated herein by reference in their entirety, as are the following: U.S. Applications 08/851,843; 08/854,050; 08/911,312; 08/912,951; 08/915,503; 08/974,549; and 08/974,584; and International Applications PCT/US97/17618 and PCT/US97/17885, which designate the U.S. and were published on October 1, 1998.

FIELD

The present invention is related to the catalytic protein subunit of human telomerase. The invention provides methods and compositions relating to medicine, molecular biology, chemistry, pharmacology, and medical diagnostic and prognostic technology.

BACKGROUND

The following discussion is intended to introduce the field of the present invention to the reader. The citation of various references in this section should not be construed as an admission of prior invention.

It has long been recognized that complete replication of the ends of eukaryotic chromosomes requires specialized cell components (Watson, 1972, *Nature New Biol.*, 239:197; Olovnikov, 1973, *J. Theor. Biol.*, 41:181). Replication of a linear DNA strand by conventional DNA polymerase requires an RNA primer, and can proceed only 5' to 3'. When the RNA bound at the extreme 5' ends of eukaryotic chromosomal DNA strands is removed, a gap is introduced, leading to a progressive shortening of daughter strands with each round of replication. This shortening of telomeres, the protein-DNA structures physically located on the ends of chromosomes, is thought to account for the phenomenon of cellular senescence or aging of normal human somatic cells *in vitro* and *in vivo*. The maintenance of telomeres is a function of a telomere-specific DNA polymerase known as telomerase. Telomerase is a ribonucleoprotein (RNP) that uses a portion of its RNA moiety as a template for telomeric DNA synthesis (Morin, 1997, *Eur. J. Cancer* 33:750). The length and integrity of telomeres and the telomerase expression status of a cell is thus related to entry of a cell into a senescent stage (*i.e.*, loss of proliferative capacity), or the ability of a cell to escape senescence, *i.e.*, to become immortal.

Consistent with the relationship of telomeres and telomerase to the proliferative capacity of a cell (*i.e.*, the ability of the cell to divide indefinitely), telomerase activity is detected in immortal cell lines and an extraordinarily diverse set of tumor tissues, but is not detected (*i.e.*, was absent or below the assay threshold) in normal somatic cell cultures or normal tissues adjacent to a tumor (see, U.S. Patent Nos. 5,629,154; 5,489,508; 5,648,215; and 5,639,613; see also, Morin, 1989, *Cell* 59: 521; Shay and Bacchetti 1997, *Eur. J. Cancer* 33:787; Kim et al., 1994, *Science* 266:2011; Counter et al., 1992, *EMBO J.* 11:1921; Counter et al., 1994, *Proc. Natl. Acad. Sci. U.S.A.* 91, 2900; Counter et al., 1994, *J. Virol.* 68:3410). Moreover, a correlation between the level of telomerase activity in

a tumor and the likely clinical outcome of the patient has been reported (e.g., U.S. Patent No. 5,639,613, *supra*; Langford et al., 1997, *Hum. Pathol.* 28:416). Thus, human telomerase is an ideal target for diagnosing and treating human diseases relating to cellular proliferation and senescence, such as cancer, or for increasing the proliferative capacity of a cell.

5

SUMMARY

In one aspect, the invention provides an isolated or recombinant hTERT polypeptide that has telomerase catalytic activity. In one embodiment, the hTERT polypeptide has a deletion of at least 25 residues in the regions corresponding to residues 192-323, 200-323, 192-271, 200-271, 222-240, 415-450, 192-323 and 415-450, or 192-271 and 415-450 of hTERT. In a related embodiment, residues 192-323, 200-323, 192-271, 200-271, 222-240, 415-450, 192-323 and 415-450, or 192-271 and 415-450 of hTERT are deleted. The invention also provides a polynucleotide comprising a nucleotide sequence encoding these hTERT polypeptides. In some embodiments, the polynucleotide includes a promoter sequence operably linked to the nucleotide sequence encoding the hTERT polypeptide.

15

The invention also provides a method of preparing recombinant telomerase by contacting a recombinant hTERT polypeptide containing a deletion as described *supra* with a telomerase RNA component under conditions such that the recombinant protein and the telomerase RNA component associate to form a telomerase enzyme capable of catalyzing the addition of nucleotides to a telomerase substrate. The hTERT polypeptide may be produced in an *in vitro* expression system and/or may be purified before the contacting step. In some embodiments, the contacting occurs in a cell.

20

The invention further provides a method for increasing the proliferative capacity of a vertebrate cell by introducing into a cell the recombinant hTERT polynucleotide encoding an hTERT deletion variant described *supra*. In a related embodiment, the invention provides a cell, such as a human cell or other mammalian cell, comprising a nucleotide sequence that encodes the hTERT deletion variant polypeptide. The invention provides such cells that have an increased proliferative capacity relative to a cell that is otherwise identical but does not comprise the recombinant polynucleotide.

25

In a different aspect of the invention, an isolated or recombinant hTERT polypeptide that has a deletion of amino acid residues 192-450, 560-565, 637-660, 638-660, 748-766, 748-764, or 1055-1071, where the residue numbering is with reference to the hTERT polypeptide having the sequence provided in Figure 1, is provided. In a related aspect, the invention provides an isolated, recombinant, or substantially purified polynucleotide encoding this polypeptide, which in some embodiments includes a promoter sequence operably linked to the nucleotide sequence encoding the hTERT polypeptide.

30

The invention also provides a method of reducing telomerase activity in a cell by introducing the polynucleotide described *supra* (i.e., having a deletion of amino acid residues 192-450, 560-565, 637-660, 638-660, 748-766, 748-764, or 1055-1071) into a cell under conditions in which it is expressed.

35

In a related embodiment, the hTERT polypeptide has one or more mutations other than, or in addition to, a deletion of at least 25 residues in the regions corresponding to residues 192-323, 200-323, 192-271, 200-271, 222-240, 415-450, 192-323 and 415-450, or 192-271 and 415-450 of hTERT.

40

In an other embodiment, the invention provides &&& METHOD

DRAWINGS

Figure 1 shows the amino acid sequence of a 1132-residue human telomerase reverse transcriptase (hTERT) protein (SEQ. ID NO:2).

Figure 2 shows the nucleotide sequence of a naturally occurring cDNA encoding the hTERT protein (SEQ. ID NO:1).

DETAILED DESCRIPTION

I. Introduction

Telomerase is a ribonucleoprotein complex (RNP) comprising an RNA component and a catalytic protein component. The catalytic protein component of human telomerase, hereinafter referred to as telomerase reverse transcriptase ("hTERT"), has been cloned, and protein, cDNA and genomic sequences determined. See, e.g., Nakamura et al., 1997, *Science* 277:955, and copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549. The sequence of a full-length native hTERT has been deposited in GenBank (Accession No. AF015950), and plasmid and phage vectors having hTERT coding sequences have been deposited with the American Type Culture Collection, Rockville, Maryland (accession numbers 209024, 209016, and 98505). The catalytic subunit protein of human telomerase has also been referred to as "hEST2" (Meyerson et al., 1997, *Cell* 90:785), "hTCS1" (Kilian et al., 1997, *Hum. Mol. Genet.* 6:2011), "TP2" (Harrington et al., 1997, *Genes Dev.* 11:3109), and "hTERT" (e.g., Greider, 1998, *Curr. Biol.* 8:R178-R181). Human TRT is also described in the aforereferenced priority applications and U.S. Patent Application Serial Numbers 08/846,017, 08/844,419, and 08/724,643. The RNA component of human telomerase (hTR) has also been characterized (see U.S. Patent No. 5,583,016). All of the aforementioned applications and publications are incorporated by reference herein in their entirety and for all purposes.

Human TRT is of extraordinary interest and value because, *inter alia*, telomerase activity in human cells and other mammalian cells correlates with cell proliferative capacity, cell immortality, and the development of a neoplastic phenotype. Thus, hTERT polypeptides, including the hTERT variants described herein, and polynucleotides encoding hTERT polypeptides, are used, *inter alia* for conferring a telomerase activity (e.g., telomerase catalytic activity, *infra*) in a telomerase-negative cell such as a cell from a human, a mammal, a vertebrate, or other eukaryote (see, e.g., Bodnar et al., 1998, *Science* 279:349 and copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549). Variants that lack at least one hTERT activity (e.g., telomerase catalytic activity) are used, *inter alia*, to inhibit telomerase activity in a cell (e.g., by acting as "dominant negative mutants"). The hTERT variants and polynucleotides encoding them, as described herein, are similarly useful in screening assays for identifying agents that modulate telomerase activity.

The hTERT variants of the present invention are characterized by one or more deletions or mutations, relative to a naturally occurring hTERT polypeptide, in defined regions of the protein, as`

Processive telomerase catalytic activity can be assayed by a variety of methods, including the "conventional assay" (Morin, 1989, *Cell* 59:521), the TRAP assay (U.S. Patent No. 5,629,154; see also, PCT publication WO 97/15687, PCT publication WO 95/13381; Krupp et al. *Nucleic Acids Res.*, 1997, 25: 919; Wright et al., 1995, *Nucl. Acids Res.* 23:3794), the "dot blot immunoassay" (U.S. Patent Application Serial Number 08/833,377), and other assays (e.g., Tatematsu et al., 1996, *Oncogene* 13:2265). The TRAPeze™ Kit (Oncor,

Inc., Gaithersburg, MD) may be used. The telomerase substrate used in these assays may have a natural telomere sequence, or may be have a synthetic oligonucleotide with a different sequence (see, e.g., Morin, 1989, *Cell* 59:521; Morin, 1991, *Nature* 353:454-56).

As used herein, an hTERT variant is considered to have a specified activity if the activity is exhibited by either the hTERT variant polypeptide without an associated hTR RNA or in an hTERT-hTR complex. Each of the hTERT activities described *supra* is also described in detail in copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549.

II. hTERT Variants Described

a) hTERT Variants with Telomerase Catalytic Activity

It has now been demonstrated that large regions of the hTERT protein can be mutated (e.g., deleted) without loss of telomerase catalytic activity. Sites of mutation (e.g., deletion) are described herein with reference to the amino acid sequence provided in Figure 1 and encoded in plasmid pGRN121 (ATCC accession number 209016); however it will be recognized that the same or equivalent mutations may be made in other hTERT polypeptides, e.g., naturally occurring variants such as polymorphic variants, hTERT fusion proteins, hTERT homologs (e.g., from non-human species), and the like. For ease of discussion, the residues of the full-length hTERT protein having a sequence as provided in Figure 1 are referred to herein by number, with the amino-terminal methionine (M) in Figure 1 numbered "1", and the carboxy-terminal aspartic acid (D) numbered "1132".

Regions of the hTERT protein that can be mutated (e.g., deleted) without abolishing telomerase catalytic activity include the regions from amino acid residues 192 to 323 (inclusive) and residues 415 to 450 (inclusive). As is demonstrated in the experiments described *infra*, all or part of either of these regions, or all or part of both of them, can be deleted without abolishing the telomerase catalytic activity of the protein. The regions from amino acid residues 192 to 323 and residues 415 to 450 may be referred to as "nonessential" regions of hTERT (i.e., not essential for telomerase catalytic activity). Thus, in various embodiments, the hTERT variants of the invention comprise deletions of, or other mutations in, these nonessential regions of hTERT. As described in Section IV, *infra*, certain mutations (e.g., deletion of residues 415-450) alter RNA-binding characteristics of the hTERT variant.

Examples of mutations that can be made in the hTERT polypeptides of the invention include deletions, insertions, substitutions, and combination of mutations. Thus, in some embodiments the mutation is a deletion of at least one, typically at least about 10, and often at least about 25, at least about 50, or at least about 100 amino acid residues relative to a naturally occurring hTERT. In alternative embodiments, the mutation is a single amino acid substitution in a "non-essential" region, or a combinations of substitutions. Substitutions may be conservative substitutions or non-conservative substitutions. In still other embodiments, the mutation is an insertion or substitution of amino acids, for example the insertion of residues that encode an epitope tag or novel proteolytic site. Substitutions may be of one or more (e.g., all) of the residues in the above-mentioned regions or may be combined with deletions so that, e.g., a shorter heterologous sequence is substituted for a longer hTERT sequence. It will be appreciated, as noted *supra*, that in some embodiments the hTERT variant has more than one different type of mutation relative to a naturally occurring hTERT protein (e.g., a deletion and a point mutation).

The hTERT variants of the invention have certain advantages compared to naturally occurring hTERT proteins. In some embodiments, mutations may confer more efficient *in vitro* expression of active hTERT (e.g., in expression systems in which shorter polypeptides are more efficiently expressed than longer polypeptides), may provide sequences that aid in purification (e.g., an epitope tag sequence), or may add a new functional moiety to the hTERT polypeptide (e.g., a 3'→5' exonuclease domain from DNA polymerase I).

As noted *supra*, the hTERT variant polypeptides of the invention comprising mutations (e.g., deletions) in the "non-essential" regions of the hTERT retain telomerase catalytic activity. These variants, and polynucleotides that encode them, are useful in any application for which other catalytically active hTERT proteins (e.g., wild-type hTERT proteins) or polynucleotides may be used, including, *inter alia*, in therapeutic, diagnostic, and screening uses. Exemplary uses of hTERT polypeptides and polynucleotides are described in additional detail in the afore cited copending applications (e.g., U.S.S.N. 08/912,951 and 08/974,549).

In one embodiment, the hTERT variant of the invention is used to increase the proliferative capacity of a cell by, e.g., increasing telomerase activity in the cell (see, Bodnar et al. *supra*, and copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549 for a detailed description of exemplary methods). Briefly, in one embodiment, a polynucleotide comprising (i) a sequence encoding the hTERT variant polypeptide; (ii) an operably linked promoter (e.g., a heterologous promoter); and, (iii) optionally polyadenylation and termination signals, enhancers, or other regulatory elements, is introduced into a target cell (e.g., by transfection, lipofection, electroporation, or any other suitable method) under conditions in which the hTERT variant polypeptide is expressed. The expression in the cell of the catalytically active hTERT variant of the invention results in increased proliferative capacity (e.g., an immortal phenotype).

In another embodiment, the hTERT variant is used for *in vitro* reconstitution (IVR) of a telomerase ribonucleoprotein (e.g., comprising the hTERT variant polypeptide and a template RNA, e.g., hTR) that has telomerase catalytic activity. *In vitro* reconstitution methods are described in, e.g., Weinrich et al., 1997, *Nat. Genet.* 17:498, and copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549. Briefly, in one embodiment, an expression vector encoding an hTERT variant of the invention is expressed in an *in vitro* expression system (e.g., a coupled transcription-translation reticulocyte lysate system such as that described in U.S. Patent No. 5,324,637). In a particular embodiment, the hTERT variant polypeptide is coexpressed with hTR. In an alternative embodiment, the hTERT variant and hTR are separately expressed and then combined (mixed) *in vitro*. In the latter method, the hTR RNA and/or hTERT polypeptide may be purified before mixing. In this context, the hTERT polypeptide is "purified" when it is separated from at least one other component of the *in vitro* expression system, and it may be purified to homogeneity as determined by standard methods (e.g., SDS-PAGE). The *in vitro* reconstituted (IVR) telomerase has a variety of uses; in particular it is useful for identifying agents that modulate hTERT activity (e.g., drug screening assays).

(b) Deletion Variants Lacking Telomerase Catalytic Activity

In an other aspect, the invention provides hTERT deletion variants that lack telomerase catalytic activity (i.e., having less than 1% of the wild type activity), as well as polynucleotides encoding the variants lacking telomerase catalytic activity. In particular, the invention provides variants comprising one or more of the following deletions relative to wild-type hTERT: residues 192-450, 637-660, 638-660, 748-766, 748-764, and 1055-1071. These variants are referred to herein as "PCA⁻ variants" (processive telomerase catalytic activity minus variants).

The PCA⁻ variant proteins and polynucleotides of the invention lacking telomerase catalytic activity are used in, *inter alia*, therapeutic, screening and other applications. For example, PCA⁻ variants are useful as dominant negative mutants for inhibition of telomerase activity in a cell. In one embodiment, a PCA⁻ variant is introduced into a cell (e.g., by transfection with a polynucleotide expression vector expressing the PCA⁻ variant), resulting in sequestration of a cell component (e.g., hTR) required for accurate telomere elongation. Thus, for example, administration of a polypeptide that binds hTR, a DNA primer, a telomerase-associated protein, or other cell component, but which does not have telomerase catalytic activity, is used to reduce endogenous telomerase

activity in the cell or to otherwise interfere with telomere extension (e.g., by displacing active telomerase from telomeric DNA). Similarly, in certain embodiments, a PCA⁻ variant of the invention having one or several hTRT activities (i.e., other than processive telomerase catalytic activity) is used for screening for agents that specifically modulate (inhibit or activate) a telomerase activity other than telomerase catalytic activity. The use of hTRT variants as dominant negative mutants, and in other applications, is described in detail in copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549.

III. Making hTRT Variants

The hTRT variant polypeptides and polynucleotides of the invention may be produced using any of a variety of techniques known in the art. In one embodiment, a polypeptide having the desired sequence, or a polynucleotide encoding the polypeptide, is chemically synthesized (see, e.g., Roberge, et al., 1995, *Science* 269:202; Brown et al., 1979, *Meth. Enzymol.* 68:109). More often, the hTRT variant polypeptides and polynucleotides of the invention are created by manipulation of a recombinant polynucleotide encoding an hTRT polypeptide. Examples of suitable recombinant polynucleotides include pGRN121, *supra*, and other hTRT cDNA and genomic sequences.

Methods for cloning and manipulation of hTRT encoding nucleic acids (e.g., site-specific mutagenesis, linker scanning mutagenesis, and the like) are well known in the art and are described, for example, in Sambrook et al., 1989, *MOLECULAR CLONING: A LABORATORY MANUAL*, 2ND ED., VOLS. 1-3, Cold Spring Harbor Laboratory, and Ausubel et al., 1997, *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, Greene Publishing and Wiley-Interscience, New York. One convenient method for producing a polynucleotide encoding a desired hTRT deletion variant is by restriction digestion and subsequent ligation of a hTRT polynucleotide, to remove a region(s) of the polynucleotide encoding the amino acid residues to be deleted. If desired, restriction sites can be introduced or removed from a synthetic or naturally occurring hTRT gene to facilitate the production and detection of variants.

Typically, the recombinant polynucleotide encoding an hTRT variant of the invention is linked to appropriate regulatory elements (e.g., promoters, enhancers, polyadenylation signals, and the like) and expressed in a cell free system (see, e.g., Weinrich et al., *supra*), in bacteria (e.g., *E. coli*), in *ex vivo* animal cell culture (see, e.g., Bodnar et al., *supra*), in animals or plants (e.g., transgenic organisms or in gene therapy applications), or by any other suitable method. Suitable expression systems are well known in the art and include those described in Weinrich et al., and Bodnar et al., both *supra*, and in e.g., copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549.

Additional hTRT variants of the invention may be made using "DNA shuffling" *in vitro* recombination technology (see, e.g., Crameri et al., 1998, *Nature* 391:288-291; Patten et al., 1997, *Curr. Opin. Biotechnol.* 8:724-733; Stemmer, 1994, *Nature* 370:389-391; Crameri et al., 1996, *Nature Medicine*, 2:1-3; Crameri et al., 1996, *Nature Biotechnology* 14:315-319; WO 95/22625; Stemmer, 1995, *Science* 270:1510; Stemmer et al., 1995, *Gene*, 164, 49-53; Stemmer, 1995, *Bio/Technology*, 13:549-553; Stemmer, 1994, *Proc. Natl. Acad. Sci. USA* 91:10747-10751). The specific deletion variants described *supra*, "wild-type hTRT" and non-human hTRT-homologs may be used in individually or various combinations as starting substrates to produce novel polypeptides with the desired activity. The activity or activities of the resulting polypeptides determined using the assays described in Section I, *supra*.

IV. Exemplary hTRT Variants

a) Generally

Exemplary hTRT variants were created by *in vitro* mutagenesis of polynucleotides encoding a full-length hTRT protein using the method of Perez et al., 1994, *J. Biol. Chem.* 269:22485-87. The mutant polynucleotides were expressed *in vitro* and telomerase reconstituted by *in vitro* mixing of hTRT and human telomerase RNA as described in Weinrich et al., 1997, *supra*. Reconstitution reactions were carried out using 0.5 pmole, 20 pmole, and, in some cases, other amounts of added hTR. Telomerase processive catalytic activity was assayed using a modified TRAP assay (Weinrich et al., 1997, *supra*). The results are summarized in Table 1.

TABLE 1

Deletion Name	Oligo	Amino acids deleted	Activity ¹
pGRN234	RT1 + RT2	none (delete <i>Nco</i> I site)	+
pGRN226	RT3A	192-323	+
RT3	RT3	200-326	+
pGRN237	RT4A	192-271	+
RT4	RT4	200-271	+
pGRN210	LM122-Nuc	222-240	+
pGRN235	RT5	415-450	+
pGRN242	RT3A+RT5	192-326 + 415-450	+
pGRN243	RT4A+RT5	192-271 + 415-450	+
pGRN240	RT3A/5	192-450	-
pGRN238	RT6A	637-660	-
RT6	RT 6	638-660	-
pGRN239	RT8A	748-766	-
RT8	RT8	748-764	-
pGRN241	RT10	1055-1071	-
pGRN236	RT11	1084-1116	-
pGRN209	LM121-WG	930-934	-
pGRN231		560-565	-

¹ "+" = at least 40% activity compared to *in vitro* reconstitution using wild-type hTRT (e.g., encoded by pGRN125; see Weinrich et al., 1997, *supra*)
 "-" = less than 1% activity .

Certain of the hTRT variants described *supra* are altered in their ability to bind hTR. The variants encoded by pGRN235, pGRN242 and pGRN243 exhibited telomerase activity when 20 pmoles hTR (template RNA) was included in the reconstitution reaction, but showed a low or undetectable level of activity when 0.5 pmoles of hTR was used. The variable activity of these variants indicates that these variants have altered (e.g.,

decreased) hTR binding activity. Thus, the region from 415 to 450 is likely involved in RNA binding (e.g., by affecting the conformation of the protein).

This result suggests that the region immediately upstream of residue 415, corresponding to the conserved "CP" domain (Bryan et al., 1998, *Proc. Nat'l. Acad. Sci.* 95:8479-8484) is a region of contact between the hTRT protein and hTR (e.g., corresponding to about residues 405 to 418 as set forth in Figure 1). This conclusion is supported by the relative lack of conservation of sequence when human and mouse TRT sequences are compared in the region corresponding to hTRT residues 415-450.

hTR binding to hTRT was also affected by mutations and deletions in the region 560-565. RNA binding was assayed by adding purified hTR to epitope tagged TRT proteins (i.e., including a FLAG sequence; Immunex Corp, Seattle WA). The hTR and protein were incubated under conditions under which tagged "wild-type" hTRT associates with template RNA (hTR), and the hTRT protein or hTRT-hTR complex (if present) were immunoprecipitated. The precipitated complex was assayed for the presence and amount of associated RNA. Deletion of residues 560-565 dramatically decreased the binding of hTR by hTRT, with the concurrent expected decrease in telomerase activity (see Table 1, pGRN231). Mutation of phenylalanine (F) to alanine (A) mutation at position 561 of hTRT (the "F561A" variant; see, Weinrich et al., 1997, *supra*) resulted in reduced binding of hTR: this variant did not effectively bind hTR in association reactions when hTR was present at 0.5 pmoles, and showed less-than wild-type binding at 20 pmoles hTR. Mutation of tyrosine at 562 to alanine similarly resulted in a loss of hTR binding activity (e.g., about a 70-80% reduction compared to the wild-type sequence). Mutation of threonine at position 564 to alanine resulted in a decrease in RNA binding by approximately 20% compared to wild-type. In contrast, mutation of residues 560 (F) and 565 (E) to alanine did not affect hTR binding. These results indicate that the region from 560-565 is involved in RNA binding, e.g., by providing residues that contact hTR.

As will be apparent to one of skill advised of these results, the telomerase reconstitution may be inhibited using peptides comprising the sequence corresponding the hTRT residues 405-418, 560-565, or fragments thereof, or peptide mimetics of such sequences. Thus, in one embodiment of the present invention, telomerase activity in a cell or an *in vitro* composition in which TRT protein and TR RNA are present, such as a telomerase reconstitution assay, is reduced by introducing to the cell or *in vitro* composition a polypeptide comprising the sequence FFYVTE (SEQ. ID NO:3), a polypeptide comprising the sequence YGVLLKTHCPLRAA (SEQ. ID NO:4), a polypeptide consisting essentially of FFYVTE (SEQ. ID NO:3), a polypeptide consisting essentially of FYVT (SEQ. ID NO:5), a polypeptide consisting essentially of YGVLLKTHCPLRAA (SEQ. ID NO:4), a fragment of at least three residues of the aforementioned polypeptides, or a peptide analog or mimetic of the polypeptide of any of the aforementioned compositions.

Peptide mimetics (or peptide analogs) are well known and are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template polypeptide (Fauchere, 1986, *Adv. Drug Res.* 15:29; Veber et al., 1985, *TINS* p.392; and Evans et al., 1987, *J. Med. Chem.* 30:1229). Generally, peptidomimetics are structurally similar to the paradigm polypeptide having the sequence from hTRT but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: -CH₂NH-, -CH₂S-, -CH₂-CH₂-, -CH'CH- (cis and trans), -COCH₂-, -CH(OH)CH₂-, and -CH₂SO-. Peptide mimetics may have significant advantages over polypeptide embodiments of this invention, including, for example: more economical production, greater chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity, and others. In addition to modifications to the peptide backbone, synthetic or non-naturally occurring amino acids can also be used to substitute for the amino acids present in the polypeptide or in the functional moiety of fusion proteins. Synthetic or

non-naturally occurring amino acids refer to amino acids which do not naturally occur in vivo but which, nevertheless, can be incorporated into the peptide structures described herein. Preferred synthetic amino acids are the d- α -amino acids of naturally occurring l- α -amino acid, mentioned above, as well as non-naturally occurring d- and l- α -amino acids represented by the formula $H_2NCH(R_5)COOH$ where R_5 is 1) a lower alkyl group, 2) a cycloalkyl group of from 3 to 7 carbon atoms, 3) a heterocycle of from 3 to 7 carbon atoms and 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, 4) an aromatic residue of from 6 to 10 carbon atoms optionally having from 1 to 3 substituents on the aromatic nucleus selected from the group consisting of hydroxyl, lower alkoxy, amino, and carboxyl, 5) -alkylene-Y where alkylene is an alkylene group of from 1 to 7 carbon atoms and Y is selected from the group consisting of (a) hydroxy, (b) amino, (c) cycloalkyl and cycloalkenyl of from 3 to 7 carbon atoms, (d) aryl of from 6 to 10 carbon atoms optionally having from 1 to 3 substituents on the aromatic nucleus selected from the group consisting of hydroxyl, lower alkoxy, amino and carboxyl, (e) heterocyclic of from 3 to 7 carbon atoms and 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, (f) -C(O)R₂ where R₂ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower alkoxy, and -NR₃R₄ where R₃ and R₄ are independently selected from the group consisting of hydrogen and lower alkyl, (g) -S(O)_nR₆ where n is an integer from 1 to 2 and R₆ is lower alkyl and with the proviso that R₅ does not define a side chain of a naturally occurring amino acid. Other preferred synthetic amino acids include amino acids wherein the amino group is separated from the carboxyl group by more than one carbon atom such as β -alanine, γ -aminobutyric acid, and the like.

It will also be recognized by those of skill upon reviewing these results that the compositions (e.g., polypeptides and mimetics) described *supra* can be used to identify telomerase association and activity inhibitors other than the disclosed polypeptide and mimetics. These compositions may be used, for example, in rational drug design for e.g., computer modeling of telomerase activity modulators (e.g., modulators that inhibit the association of TRT and TR or that catalyze the disassociation of the telomerase complex), as positive controls in screens for modulators of telomerase activity, or in competition assays with candidate telomerase activity modulators.

b) Methods

Mutagenesis of the hTRT coding sequence of pGRN125 was carried out using the methods described by Perez et al., 1994, *J. Biol. Chem.* 269:22485-87. Most of the deletion mutants were generated from the plasmid pGRN125 (Weinrich et al., 1997, *supra*). Deletion mutants pGRN235 and pGRN236 were made in a secondary round of mutagenesis in an altered pGRN234. pGRN234 was generated by mutating (deleting) the *Nco* I site in pGRN125 (changing CAC to CAT in the histidine residue at position 754) and introducing a new *Nco* I site at the translation start site (ATG). Table 2 shows exemplary oligonucleotides used to generate the plasmids expressing the deletion variants of the invention.

TABLE 2

Oligo Name	Oligo sequence 5'-3'	length	Description	SEQ. ID NO:
RT1	GAAGGCCGCCCCACGGGCACGTCCGC	25	Mutagenesis oligo to delete Nco I site from pGRN125	6
RT2	CCCGGCCACCCCAGCCATGGCGCGCGCTCCCC		Mutagenesis oligo to create Nco I site @ ATG of pGRN 125	7
RT5	TACGGGGTGCTCCTCAAGACGCAC TGCCCGCTGCTCCGCCAGCACAGC AGCCCCTGGCAG	60	Mutagenesis oligo to create a deletion of aa 415-450 in pGRN125	8
RT10	TACTCCATCCTGAAAGCCAAGAAGCAGGGCTGTGCCACCAAGCATTCTGCTCAAGCTG	60	Mutagenesis oligo to create a deletion of aa 1055-1071 in pGRN125	9
RT11	CTGTGCCACCAAGCATTCTGCTCAAGCTGGCCGAGCCAACCCGGCCTGCTCAGAC	60	Mutagenesis oligo to create a deletion of aa 1083-1116 in pGRN125. Oligo creates a NheI site.	10
RT3A	ACTCAGGCCCGGCCCGGCCACA CGCTAGCGAGACCAAGCACTTCCTCTACTCCTCAGGC	60	Mutagenesis oligo to create a deletion of aa 192-323 in pGRN125. Oligo creates a NheI site.	11
RT4A	ACTCAGGCCCGGCCCGGCCACA CGCTAGCGTGGTGTACCTGCCAGACCCGCCGAAGAA	60	Mutagenesis oligo to create a deletion of aa 192-271 in pGRN125. Oligo creates a NheI site.	12
RT6A	ATCCCCAAGCCTGACGGGCTGCGGCCGATTGTTAACATGCTGTTTCAGCGTGCTCAACTACGAGCGGGCG	69	Mutagenesis oligo to create a deletion of aa 638-660 in pGRN125. Oligo creates a Hpa I site.	13
RT8A	ACGTAAGTGCCTGCGTGGTATGCCGTGGTCACAGATCTCCAGCCGTACATGCGACAGTTCGTG	63	Mutagenesis oligo to create a deletion of aa 748-766 in pGRN125. Oligo creates a Bgl II site.	14
RT3A/5	ACTCAGGCCCGGCCCGGCCACA CGCTAGCCTGCTCCGCCAGCACAGCAGCCCCTGGCAG	60	Mutagenesis oligo to create a deletion of aa 192-450 in pGRN125. Oligo creates a NheI site.	15
LM121-WG	GTTCAGATGCCGGCCACGGCCTATTCCCTCTAGATACCCGGACCCTGGAGGTGCAGAGCGAC	63	Mutagenesis oligo to delete aa 930-934. Oligo introduces a new XbaI site	16
LM122-Nuc	CCCTGGGCCTGCCAGCCCCGGGTGCCGGCGCTGCCCTGAGCCGGA GCGG	50	Mutagenesis oligo to delete aa 222-240. Oligo introduces a new Nae I site	17
RT3	GCTAGTGGACCCCGAAGGCGTCTGGATGCGAGACCAAGCACTTCCTCTACTCCTCAGGC	60	Mutagenesis oligo to create a deletion of aa200-323 in pGRN125	18
RT4	GCTAGTGGACCCCGAAGGCGTCTGGATGCGTGGTGTACCTGCCAGACCCGCCGAAGAA	60	Mutagenesis oligo to create a deletion of aa 200-271 in pGRN125	19
RT6	GACGGGCTGCGGCCGATTGTGAACATGGACCTGTTTCAGCGTGTCAAC TACGAGCGGGCG	60	Mutagenesis oligo to create a deletion of aa 638-660 in pGRN125	20
RT8	ACGTAAGTGCCTGCGTGGTATGCCGTGGTCACCTTGACAGACCTCCAGCCGTACATGCGA	60	Mutagenesis oligo to create a deletion of aa 748-764 in pGRN125	21

V. Definitions

The following terms are defined *infra* to provide additional guidance to one of skill in the practice of the invention:

As used herein, a polypeptide region in a first polypeptide "corresponds" to a region in a second polypeptide when the amino acid sequences of the two regions, or flanking the two regions, are the same or substantially identical. Sequences can be aligned by inspection (e.g., alignment of identical sequences) or by computer implemented alignment of the two sequences. Thus, for example, the residues 192 to 323 of the hTRT polypeptide having the sequence set forth in Figure 1 "correspond" to residues in the same position in a hTRT polypeptide that differs from the Figure 1 sequence due to polymorphic variation, or other mutations or deletions (e.g., when the two polypeptides are optimally aligned). Alignments may also be carried out using the GAP computer program, version 6.0 (Devereux et al, 1984, *Nucl. Acid. Res.* 12:387; available from the University of Wisconsin Genetics Computer Group, Madison, WI). The GAP program utilizes the alignment method of Needleham and Wunsch, 1970 *J. Mol. Biol.* 48: 443-453 as revised by Smith and Waterman, 1981, *Adv. Appl. Math* 2:482. The preferred default parameters for the GAP program include (1) the weighted comparison matrix of Gribskov and Burgess, 1986, *Nucl. Acid. Res.* 14:6745 as described by Schwartz and Dayhoff, eds., 1979, ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Alternatively, alignments can be carried out using the BLAST algorithm, which is described in Altschul et al., 1990, *J. Mol. Biol.* 215:403-410 using as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff & Henikoff, 1989, *Proc. Natl. Acad. Sci. USA* 89:10915); alignments (B) of 50, expectation (E) of 10, M=5, and N=-4. A modification of BLAST, the "Gapped BLAST" allows gaps to be introduced into the alignments that are returned (Altschul et al., 1997, *Nucleic Acids Res* 1:3389-3402). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

When referring to an "activity" of an hTRT variant, a variant is considered to be active in an assay of it displays at least 40% of the activity characteristic of the hTRT polypeptide having the sequence set forth in Fig. 1 ("wild type"). A variant is considered to lack activity when it has less than 1% of the "wild type" activity. A variant with greater than 1% activity and less than 40% activity has "intermediate activity."

As used herein, "conservative substitution," refers to substitution of amino acids with other amino acids having similar properties (e.g., acidic, basic, positively or negatively charged, polar or non-polar). The following six groups each contain amino acids that are conservative substitutions for one another: 1) alanine (A), serine (S), threonine (T); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); and 6) phenylalanine (F), tyrosine (Y), tryptophan (W) (see also, Creighton, 1984, *PROTEINS*, W. H. Freeman and Company).

All publications and patent documents cited in this application are incorporated by reference in their entirety and for all purposes to the same extent as if each individual publication or patent document were so individually denoted.

SEQUENCE LISTING

<110> Morin, Gregg B.
Geron Corporation

<120> Human Telomerase Catalytic Subunit Variants

<130> 018/258c

<140> 00/000,000

<141> 2001-00-00

<140> US 09/128,354

<141> 1998-08-03

<150> US 09/052,864

<151> 1998-03-31

<160> 21

<170> PatentIn Ver. 2.0

<210> 1

<211> 4015

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (56)..(3454)

<223> human telomerase reverse transcriptase (hTERT) cDNA

<400> 1

gcagcgctgc gtcctgctgc gcacgtggga agccctggcc ccggccaccc ccgcg atg 58
Met
1

ccg cgc gct ccc cgc tgc cga gcc gtg cgc tcc ctg ctg cgc agc cac 106
Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser His
5 10 15

tac cgc gag gtg ctg ccg ctg gcc acg ttc gtg cgg cgc ctg ggg ccc 154
Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly Pro
20 25 30

cag ggc tgg cgg ctg gtg cag cgc ggg gac ccg gcg gct ttc cgc gcg 202
Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg Ala
35 40 45

ctg gtg gcc cag tgc ctg gtg tgc gtg ccc tgg gac gca cgg ccg ccc 250
Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro Pro
50 55 60 65

ccc gcc gcc ccc tcc ttc cgc cag gtg tcc tgc ctg aag gag ctg gtg 298
Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu Val
70 75 80

gcc cga gtg ctg cag agg ctg tgc gag cgc ggc gcg aag aac gtg ctg 346
Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn Val Leu
85 90 95

gcc ttc gcc ttc gcg ctg ctg gac ggg gcc cgc ggg gcc ccc ccc gag 394
Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro Glu
100 105 110

gcc ttc acc acc agc gtg cgc agc tac ctg ccc aac acg gtg acc gac 442

Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr Asp 115 120 125	
gca ctg cgg ggg agc ggg gcg tgg ggg ctg ctg ctg cgc cgc gtg ggc Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val Gly 130 135 140 145	490
gac gac gtg ctg gtt cac ctg ctg gca cgc tgc gcg ctc ttt gtg ctg Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe Val Leu 150 155 160	538
gtg gct ccc agc tgc gcc tac cag gtg tgc ggg ccg ccg ctg tac cag Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr Gln 165 170 175	586
ctc ggc gct gcc act cag gcc cgg ccc ccg cca cac gct agt gga ccc Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser Gly Pro 180 185 190	634
cga agg cgt ctg gga tgc gaa cgg gcc tgg aac cat agc gtc agg gag Arg Arg Arg Leu Gly Cys Glu Arg Ala Trp Asn His Ser Val Arg Glu 195 200 205	682
gcc ggg gtc ccc ctg ggc ctg cca gcc ccg ggt gcg agg agg cgc ggg Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg Gly 210 215 220 225	730
ggc agt gcc agc cga agt ctg ccg ttg ccc aag agg ccc agg cgt ggc Gly Ser Ala Ser Arg Ser Leu Pro Leu Pro Lys Arg Pro Arg Arg Gly 230 235 240	778
gct gcc cct gag ccg gag cgg acg ccc gtt ggg cag ggg tcc tgg gcc Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp Ala 245 250 255	826
cac ccg ggc agg acg cgt gga ccg agt gac cgt ggt ttc tgt gtg gtg His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val Val 260 265 270	874
tca cct gcc aga ccc gcc gaa gaa gcc acc tct ttg gag ggt gcg ctc Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala Leu 275 280 285	922
tct ggc acg cgc cac tcc cac cca tcc gtg ggc cgc cag cac cac gcg Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His Ala 290 295 300 305	970
ggc ccc cca tcc aca tcg cgg cca cca cgt ccc tgg gac acg cct tgt Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr Pro Cys 310 315 320	1018
ccc ccg gtg tac gcc gag acc aag cac ttc ctc tac tcc tca ggc gac Pro Pro Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser Gly Asp 325 330 335	1066
aag gag cag ctg cgg ccc tcc ttc cta ctc agc tct ctg agg ccc agc Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg Pro Ser 340 345 350	1114
ctg act ggc gct cgg agg ctc gtg gag acc atc ttt ctg ggt tcc agg Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser Arg 355 360 365	1162
ccc tgg atg cca ggg act ccc cgc agg ttg ccc cgc ctg ccc cag cgc Pro Trp Met Pro Gly Thr Pro Arg Arg Leu Pro Arg Leu Pro Gln Arg 370 375 380 385	1210
tac tgg caa atg cgg ccc ctg ttt ctg gag ctg ctt ggg aac cac gcg	1258

Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His Ala	
390 395 400	
cag tgc ccc tac ggg gtg ctc ctc aag acg cac tgc ccg ctg cga gct	1306
Gln Cys Pro Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg Ala	
405 410 415	
gcg gtc acc cca gca gcc ggt gtc tgt gcc cgg gag aag ccc cag ggc	1354
Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln Gly	
420 425 430	
tct gtg gcg gcc ccc gag gag gag gac aca gac ccc cgt cgc ctg gtg	1402
Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu Val	
435 440 445	
cag ctg ctc cgc cag cac agc agc ccc tgg cag gtg tac ggc ttc gtg	1450
Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe Val	
450 455 460 465	
cgg gcc tgc ctg cgc cgg ctg gtg ccc cca ggc ctc tgg ggc tcc agg	1498
Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser Arg	
470 475 480	
cac aac gaa cgc cgc ttc ctc agg aac acc aag aag ttc atc tcc ctg	1546
His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser Leu	
485 490 495	
ggg aag cat gcc aag ctc tcg ctg cag gag ctg acg tgg aag atg agc	1594
Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met Ser	
500 505 510	
gtg cgg gac tgc gct tgg ctg cgc agg agc cca ggg gtt ggc tgt gtt	1642
Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys Val	
515 520 525	
ccg gcc gca gag cac cgt ctg cgt gag gag atc ctg gcc aag ttc ctg	1690
Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe Leu	
530 535 540 545	
cac tgg ctg atg agt gtg tac gtc gtc gag ctg ctc agg tct ttc ttt	1738
His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe Phe	
550 555 560	
tat gtc acg gag acc acg ttt caa aag aac agg ctc ttt ttc tac cgg	1786
Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr Arg	
565 570 575	
aag agt gtc tgg agc aag ttg caa agc att gga atc aga cag cac ttg	1834
Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His Leu	
580 585 590	
aag agg gtg cag ctg cgg gag ctg tcg gaa gca gag gtc agg cag cat	1882
Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln His	
595 600 605	
cgg gaa gcc agg ccc gcc ctg ctg acg tcc aga ctc cgc ttc atc ccc	1930
Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro	
610 615 620 625	
aag cct gac ggg ctg cgg ccg att gtg aac atg gac tac gtc gtg gga	1978
Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val Gly	
630 635 640	
gcc aga acg ttc cgc aga gaa aag agg gcc gag cgt ctc acc tcg agg	2026
Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser Arg	
645 650 655	
gtg aag gca ctg ttc agc gtg ctc aac tac gag cgg gcg cgg cgc ccc	2074

Val	Lys	Ala	Leu	Phe	Ser	Val	Leu	Asn	Tyr	Glu	Arg	Ala	Arg	Arg	Pro		
		660					665					670					
ggc	ctc	ctg	ggc	gcc	tct	gtg	ctg	ggc	ctg	gac	gat	atc	cac	agg	gcc	2122	
Gly	Leu	Leu	Gly	Ala	Ser	Val	Leu	Gly	Leu	Asp	Asp	Ile	His	Arg	Ala		
		675					680				685						
tgg	cgc	acc	ttc	gtg	ctg	cgt	gtg	cgg	gcc	cag	gac	ccg	ccg	cct	gag	2170	
Trp	Arg	Thr	Phe	Val	Leu	Arg	Val	Arg	Ala	Gln	Asp	Pro	Pro	Pro	Glu		
						695				700					705		
ctg	tac	ttt	gtc	aag	gtg	gat	gtg	acg	ggc	gcg	tac	gac	acc	atc	ccc	2218	
Leu	Tyr	Phe	Val	Lys	Val	Asp	Val	Thr	Gly	Ala	Tyr	Asp	Thr	Ile	Pro		
				710					715					720			
cag	gac	agg	ctc	acg	gag	gtc	atc	gcc	agc	atc	atc	aaa	ccc	cag	aac	2266	
Gln	Asp	Arg	Leu	Thr	Glu	Val	Ile	Ala	Ser	Ile	Ile	Lys	Pro	Gln	Asn		
				725				730					735				
acg	tac	tgc	gtg	cgt	cgg	tat	gcc	gtg	gtc	cag	aag	gcc	gcc	cat	ggg	2314	
Thr	Tyr	Cys	Val	Arg	Arg	Tyr	Ala	Val	Val	Gln	Lys	Ala	Ala	His	Gly		
		740					745					750					
cac	gtc	cgc	aag	gcc	ttc	aag	agc	cac	gtc	tct	acc	ttg	aca	gac	ctc	2362	
His	Val	Arg	Lys	Ala	Phe	Lys	Ser	His	Val	Ser	Thr	Leu	Thr	Asp	Leu		
							760				765						
cag	ccg	tac	atg	cga	cag	ttc	gtg	gct	cac	ctg	cag	gag	acc	agc	ccg	2410	
Gln	Pro	Tyr	Met	Arg	Gln	Phe	Val	Ala	His	Leu	Gln	Glu	Thr	Ser	Pro		
						775				780					785		
ctg	agg	gat	gcc	gtc	gtc	atc	gag	cag	agc	tcc	tcc	ctg	aat	gag	gcc	2458	
Leu	Arg	Asp	Ala	Val	Val	Ile	Glu	Gln	Ser	Ser	Ser	Leu	Asn	Glu	Ala		
						790				795				800			
agc	agt	ggc	ctc	ttc	gac	gtc	ttc	cta	cgc	ttc	atg	tgc	cac	cac	gcc	2506	
Ser	Ser	Gly	Leu	Phe	Asp	Val	Phe	Leu	Arg	Phe	Met	Cys	His	His	Ala		
				805				810					815				
gtg	cgc	atc	agg	ggc	aag	tcc	tac	gtc	cag	tgc	cag	ggg	atc	ccg	cag	2554	
Val	Arg	Ile	Arg	Gly	Lys	Ser	Tyr	Val	Gln	Cys	Gln	Gly	Ile	Pro	Gln		
						820		825				830					
ggc	tcc	atc	ctc	tcc	acg	ctg	ctc	tgc	agc	ctg	tgc	tac	ggc	gac	atg	2602	
Gly	Ser	Ile	Leu	Ser	Thr	Leu	Leu	Cys	Ser	Leu	Cys	Tyr	Gly	Asp	Met		
						840				845							
gag	aac	aag	ctg	ttt	gcg	ggg	att	cgg	cgg	gac	ggg	ctg	ctc	ctg	cgt	2650	
Glu	Asn	Lys	Leu	Phe	Ala	Gly	Ile	Arg	Arg	Asp	Gly	Leu	Leu	Leu	Arg		
						855				860					865		
ttg	gtg	gat	gat	ttc	ttg	ttg	gtg	aca	cct	cac	ctc	acc	cac	gcg	aaa	2698	
Leu	Val	Asp	Asp	Phe	Leu	Leu	Val	Thr	Pro	His	Leu	Thr	His	Ala	Lys		
						870			875					880			
acc	ttc	ctc	agg	acc	ctg	gtc	cga	ggt	gtc	cct	gag	tat	ggc	tgc	gtg	2746	
Thr	Phe	Leu	Arg	Thr	Leu	Val	Arg	Gly	Val	Pro	Glu	Tyr	Gly	Cys	Val		
						885			890				895				
gtg	aac	ttg	cgg	aag	aca	gtg	gtg	aac	ttc	cct	gta	gaa	gac	gag	gcc	2794	
Val	Asn	Leu	Arg	Lys	Thr	Val	Val	Asn	Phe	Pro	Val	Glu	Asp	Glu	Ala		
						900		905				910					
ctg	ggt	ggc	acg	gct	ttt	gtt	cag	atg	ccg	gcc	cac	ggc	cta	ttc	ccc	2842	
Leu	Gly	Gly	Thr	Ala	Phe	Val	Gln	Met	Pro	Ala	His	Gly	Leu	Phe	Pro		
						915		920			925						
tgg	tgc	ggc	ctg	ctg	ctg	gat	acc	cgg	acc	ctg	gag	gtg	cag	agc	gac	2890	

Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln Ser Asp
930 935 940 945

tac tcc agc tat gcc cgg acc tcc atc aga gcc agt ctc acc ttc aac 2938
Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr Phe Asn
950 955 960

cgc ggc ttc aag gct ggg agg aac atg cgt cgc aaa ctc ttt ggg gtc 2986
Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe Gly Val
965 970 975

ttg cgg ctg aag tgt cac agc ctg ttt ctg gat ttg cag gtg aac agc 3034
Leu Arg Leu Lys Cys His Ser Leu Phe Leu Asp Leu Gln Val Asn Ser
980 985 990

ctc cag acg gtg tgc acc aac atc tac aag atc ctc ctg ctg cag gcg 3082
Leu Gln Thr Val Cys Thr Asn Ile Tyr Lys Ile Leu Leu Leu Gln Ala
995 1000 1005

tac agg ttt cac gca tgt gtg ctg cag ctc cca ttt cat cag caa gtt 3130
Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe His Gln Gln Val
1010 1015 1020 1025

tgg aag aac ccc aca ttt ttc ctg cgc gtc atc tct gac acg gcc tcc 3178
Trp Lys Asn Pro Thr Phe Phe Leu Arg Val Ile Ser Asp Thr Ala Ser
1030 1035 1040

ctc tgc tac tcc atc ctg aaa gcc aag aac gca ggg atg tcg ctg ggg 3226
Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly Met Ser Leu Gly
1045 1050 1055

gcc aag ggc gcc gcc ggc cct ctg ccc tcc gag gcc gtg cag tgg ctg 3274
Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu Ala Val Gln Trp Leu
1060 1065 1070

tgc cac caa gca ttc ctg ctc aag ctg act cga cac cgt gtc acc tac 3322
Cys His Gln Ala Phe Leu Leu Lys Leu Thr Arg His Arg Val Thr Tyr
1075 1080 1085

gtg cca ctc ctg ggg tca ctc agg aca gcc cag acg cag ctg agt cgg 3370
Val Pro Leu Leu Gly Ser Leu Arg Thr Ala Gln Thr Gln Leu Ser Arg
1090 1095 1100 1105

aag ctc ccg ggg acg acg ctg act gcc ctg gag gcc gca gcc aac ccg 3418
Lys Leu Pro Gly Thr Thr Leu Thr Ala Leu Glu Ala Ala Asn Pro
1110 1115 1120

gca ctg ccc tca gac ttc aag acc atc ctg gac tga tggccacccg 3464
Ala Leu Pro Ser Asp Phe Lys Thr Ile Leu Asp
1125 1130

cccacagcca ggccgagagc agacaccagc agccctgtca cgccgggctc tacgtcccag 3524

ggagggaggg gcggcccaca cccaggcccg caccgctggg agtctgaggc ctgagtgagt 3584

gtttggccga ggctgcatg tccggctgaa ggctgagtgt ccggctgagg cctgagcgag 3644

tgtccagcca agggctgagt gtccagcaca cctgccgtct tcaactcccc acaggctggc 3704

gctcggctcc accccagggc cagcttttcc tcaccaggag cccggcttcc actccccaca 3764

taggaatagt ccatccccag attcgccatt gttcacccct cgccctgccc tcctttgcct 3824

tccaccccca ccatccaggt ggagaccctg agaaggaccc tgggagctct gggaatttgg 3884

agtgacaaa ggtgtgccct gtacacaggc gaggaccctg cacctggatg ggggtccctg 3944

tgggtcaaat tggggggagg tgctgtggga gtaaaatact gaatatatga gtttttcagt 4004

tttgaaaaa a

4015

<210> 2
<211> 1132
<212> PRT
<213> Homo sapiens

<400> 2

```

Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser
 1           5           10           15

His Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly
          20           25           30

Pro Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg
          35           40           45

Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro
 50           55           60

Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu
 65           70           75           80

Val Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn Val
          85           90           95

Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro
          100          105          110

Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr
          115          120          125

Asp Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val
          130          135          140

Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe Val
          145          150          155          160

Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr
          165          170          175

Gln Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser Gly
          180          185          190

Pro Arg Arg Arg Leu Gly Cys Glu Arg Ala Trp Asn His Ser Val Arg
          195          200          205

Glu Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg
          210          215          220

Gly Gly Ser Ala Ser Arg Ser Leu Pro Leu Pro Lys Arg Pro Arg Arg
          225          230          235          240

Gly Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp
          245          250          255

Ala His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val
          260          265          270

Val Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala
          275          280          285

Leu Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His
          290          295          300

Ala Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr Pro

```

305		310		315		320									
Cys	Pro	Pro	Val	Tyr	Ala	Glu	Thr	Lys	His	Phe	Leu	Tyr	Ser	Ser	Gly
			325						330					335	
Asp	Lys	Glu	Gln	Leu	Arg	Pro	Ser	Phe	Leu	Leu	Ser	Ser	Leu	Arg	Pro
		340						345					350		
Ser	Leu	Thr	Gly	Ala	Arg	Arg	Leu	Val	Glu	Thr	Ile	Phe	Leu	Gly	Ser
		355					360					365			
Arg	Pro	Trp	Met	Pro	Gly	Thr	Pro	Arg	Arg	Leu	Pro	Arg	Leu	Pro	Gln
	370					375					380				
Arg	Tyr	Trp	Gln	Met	Arg	Pro	Leu	Phe	Leu	Glu	Leu	Leu	Gly	Asn	His
385					390					395					400
Ala	Gln	Cys	Pro	Tyr	Gly	Val	Leu	Leu	Lys	Thr	His	Cys	Pro	Leu	Arg
			405						410						415
Ala	Ala	Val	Thr	Pro	Ala	Ala	Gly	Val	Cys	Ala	Arg	Glu	Lys	Pro	Gln
		420						425					430		
Gly	Ser	Val	Ala	Ala	Pro	Glu	Glu	Glu	Asp	Thr	Asp	Pro	Arg	Arg	Leu
		435					440					445			
Val	Gln	Leu	Leu	Arg	Gln	His	Ser	Ser	Pro	Trp	Gln	Val	Tyr	Gly	Phe
	450					455					460				
Val	Arg	Ala	Cys	Leu	Arg	Arg	Leu	Val	Pro	Pro	Gly	Leu	Trp	Gly	Ser
465					470				475						480
Arg	His	Asn	Glu	Arg	Arg	Phe	Leu	Arg	Asn	Thr	Lys	Lys	Phe	Ile	Ser
			485						490					495	
Leu	Gly	Lys	His	Ala	Lys	Leu	Ser	Leu	Gln	Glu	Leu	Thr	Trp	Lys	Met
			500					505					510		
Ser	Val	Arg	Asp	Cys	Ala	Trp	Leu	Arg	Arg	Ser	Pro	Gly	Val	Gly	Cys
		515					520					525			
Val	Pro	Ala	Ala	Glu	His	Arg	Leu	Arg	Glu	Glu	Ile	Leu	Ala	Lys	Phe
	530					535					540				
Leu	His	Trp	Leu	Met	Ser	Val	Tyr	Val	Val	Glu	Leu	Leu	Arg	Ser	Phe
545					550					555					560
Phe	Tyr	Val	Thr	Glu	Thr	Thr	Phe	Gln	Lys	Asn	Arg	Leu	Phe	Phe	Tyr
			565						570					575	
Arg	Lys	Ser	Val	Trp	Ser	Lys	Leu	Gln	Ser	Ile	Gly	Ile	Arg	Gln	His
			580					585					590		
Leu	Lys	Arg	Val	Gln	Leu	Arg	Glu	Leu	Ser	Glu	Ala	Glu	Val	Arg	Gln
		595					600					605			
His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile
	610					615					620				
Pro	Lys	Pro	Asp	Gly	Leu	Arg	Pro	Ile	Val	Asn	Met	Asp	Tyr	Val	Val
625					630					635					640
Gly	Ala	Arg	Thr	Phe	Arg	Arg	Glu	Lys	Arg	Ala	Glu	Arg	Leu	Thr	Ser
			645						650					655	
Arg	Val	Lys	Ala	Leu	Phe	Ser	Val	Leu	Asn	Tyr	Glu	Arg	Ala	Arg	Arg
			660					665					670		

Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly Met Ser Leu
1045 1050 1055

Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu Ala Val Gln Trp
1060 1065 1070

Leu Cys His Gln Ala Phe Leu Leu Lys Leu Thr Arg His Arg Val Thr
1075 1080 1085

Tyr Val Pro Leu Leu Gly Ser Leu Arg Thr Ala Gln Thr Gln Leu Ser
1090 1095 1100

Arg Lys Leu Pro Gly Thr Thr Leu Thr Ala Leu Glu Ala Ala Ala Asn
1105 1110 1115 1120

Pro Ala Leu Pro Ser Asp Phe Lys Thr Ile Leu Asp
1125 1130

<210> 3
<211> 6
<212> PRT
<213> Homo sapiens

<220>
<221> PEPTIDE
<222> (1)..(6)
<223> amino acid positions 560-565 from hTRT

<400> 3
Phe Phe Tyr Val Thr Glu
1 5

<210> 4
<211> 14
<212> PRT
<213> Homo sapiens

<220>
<221> PEPTIDE
<222> (1)..(14)
<223> amino acid positions 405-418 from hTRT

<400> 4
Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg Ala Ala
1 5 10

<210> 5
<211> 4
<212> PRT
<213> Homo sapiens

<220>
<221> PEPTIDE
<222> (1)..(4)
<223> amino acid positions 561-564 from hTRT

<400> 5
Phe Tyr Val Thr
1

<210> 6
<211> 25
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT1 oligo

<400> 6

gaaggccgcc cacgggcacg tccgc

25

<210> 7

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT2 oligo

<400> 7

cccggccacc ccagccatgg cgcgcgctcc cc

32

<210> 8

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT5 oligo

<400> 8

tacggggtgc tcctcaagac gactgcccg ctgctccgcc agcacagcag cccctggcag 60

<210> 9

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT10 oligo

<400> 9

tactccatcc tgaaagccaa gaacgcaggg ctgtgccacc aagcattcct gctcaagctg 60

<210> 10

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT11 oligo

<400> 10

ctgtgccacc aagcattcct gctcaagctg gccgcagcca acccggcact gccctcagac 60

<210> 11

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT3A oligo

<400> 11

actcaggccc ggccccgcc acacgctagc gagaccaagc acttcctcta ctcctcaggc 60

<210> 12
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT4A oligo

<400> 12
actcaggccc ggccccgcc acacgctagc gtggtgtcac ctgccagacc cgccgaagaa 60

<210> 13
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT6A oligo

<400> 13
atccccaagc ctgacgggct gcggccgatt gttaacatgc tgttcagcgt gctcaactac 60
gagcgggacg 69

<210> 14
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT8A oligo

<400> 14
acgtactgcg tgcgtcggtg tgccgtggtc acagatctcc agccgtacat gcgacagtgc 60
gtg 63

<210> 15
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT3A/5 oligo

<400> 15
actcaggccc ggccccgcc acacgctagc ctgctccgcc agcacagcag cccctggcag 60

<210> 16
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LM121-WG oligo

<400> 16
gttcagatgc cggccacagg cctattccct ctagataccc ggaccctgga ggtgcagagc 60
gac 63

<210> 17

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LM122-Nuc oligo

<400> 17
ccctgggcct gccagcccg ggtgccggcg ctgccctga gccggagcgg 50

<210> 18
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT3 oligo

<400> 18
gctagtggac cccgaaggcg tctgggatgc gagaccaagc acttcctcta ctctcaggc 60

<210> 19
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT4 oligo

<400> 19
gctagtggac cccgaaggcg tctgggatgc gtggtgtcac ctgccagacc cgccgaagaa 60

<210> 20
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT6 oligo

<400> 20
gacgggctgc ggccgattgt gaacatggac ctgttcagcg tgctcaacta cgagcgggcg 60

<210> 21
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT8 oligo

<400> 21
acgtactgcg tgcgtcggta tgccgtggtc accttgacag acctccagcc gtacatgcga 60